About Bliss GVS Pharma Limited

Bliss GVS Pharma Limited is a Mumbai-headquartered pharmaceutical company incorporated on December 11, 1984. It manufactures, markets, trades and exports pharmaceutical products, and also provides product development services—activities that collectively account for 100% of its turnover. The company’s shares are listed on BSE and NSE, and its registered office is in Andheri (East), Mumbai. Its portfolio spans 150+ brands across 50+ therapeutic segments in 16+ dosage forms, reflecting a diversified presence across over-the-counter and prescription categories.

The company’s R&D Centre in Mumbai is certified by the Department of Scientific & Industrial Research (DSIR) and is equipped with advanced instrumentation for formulation and analytical development, underscoring its focus on quality and innovation. On the manufacturing front, operations are anchored in India with 4 plants and 3 domestic offices, supported by an overseas office, giving the company an operational footprint that combines scale with proximity to key markets. Markets served extend to 44 countries, and exports contributed 92.27% of total turnover in the latest year, highlighting the company’s strong international orientation; major customers are pharmaceutical distributors.

Bliss GVS Pharma Limited Key Milestones

A recognised milestone is Bliss GVS’s status as India’s first EU‑GMP certified suppository manufacturer. Its facilities comply with cGMP standards under multiple regimes, including EU GMP, US FDA and WHO GMP, reflecting robust quality assurance and regulatory adherence. At the Group level, the company had 6 subsidiaries as of the reporting year, supporting its presence across geographies and product lines.

Bliss GVS Pharma Limited Key Management

•  Dr. Nandkumar K. Chodankar – Chairman
•  Gagan Harsh Sharma – Managing Director
•  Deepak Sawant – Chief Financial Officer
•  Aditi Bhatt – Company Secretary

Latest Updates of Bliss GVS Pharma Limited

• Group structure optimisation: The Board approved an internal restructuring of foreign subsidiaries. Key steps included transferring the entire equity stake of Asterisk Lifesciences (GH) Ltd. to Bliss GVS International Pte. Ltd. (Singapore) on February 29, 2024; initiating voluntary liquidation of Asterisk Lifesciences DRC, with loss of control effective February 19, 2024; and converting a USD 5 Million loan to equity in the Singapore subsidiary on February 23, 2024.
• Product pipeline momentum: The company launched 10+ new products during the year, supporting its focus on portfolio expansion and market relevance across therapeutic areas and dosage forms.
• Quality and regulatory standing: Bliss GVS reiterated its strong compliance track record, with facilities aligned to EU GMP, US FDA and WHO GMP standards; notably, it remains India’s first EU‑GMP certified suppository manufacturer.
• Credit profile: CRISIL reaffirmed ratings as on March 31, 2025—CRISIL BBB+/Stable for long-term facilities and CRISIL A2 for short-term facilities—supporting the company’s access to funding for ongoing operations and growth.
• Governance and continuity: The Board reported that no significant and material orders were passed by regulators, courts or tribunals that would impact the company’s going concern status or future operations during the year.